Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Mononuclear cell subsets in peripheral blood, in vitro production of interleukin-2 (IL-2) and gamma interferon (IFN gamma), spontaneous cell-mediated cytotoxicity (SCMC) and circulating levels of Type I IFN, neopterin, beta-2 microglobulin (B2-M), immunoglobulins and complement fractions were studied in 33 patients with Hodgkin's disease (HD) in complete remission. The mean percentages, but not the absolute numbers, of T-lymphocytes expressing pan-T markers (OKT11, OKT3, ER, E-AET R) were significantly decreased compared with control values. Furthermore, patients showed a selective loss of OKT4+ cells, as well as increased percentages and numbers of Leu7+ and OKIa+ lymphocytes, and of OKM1+, LeuM2+, and LeuM3+ cells. OKT4+ cell depletion was a characteristic of patients with shorter time since beginning of remission as well as of those with nodular sclerosis (NS), mixed cellularity Hodgkin's disease (MC-HD), and systemic symptoms at diagnosis. Multifactorial statistical analysis carried out to investigate the effect of disease characteristics and the time since remission began on peripheral mononuclear blood cell (PMBC) subsets showed that histologic condition was the single best predictor of T-cell pool or OKT4+ cell subset size. Time since remission duration and other disease-related factors determined differences in the percentages, but not in the absolute numbers, of T-cell fractions. In addition, neither the disease features nor the time since remission duration determined significant differences in the absolute number of non-T-mononuclear cells in the various patient groups. Patients displayed decreased in vitro synthesis of IL-2 and IFN gamma. The values of SCMC, Type I IFN, neopterin, B2-M, immunoglobulins, and complement fractions did not differ greatly from those of controls.
 ...
PMID:Immunologic profile in patients with Hodgkin's disease in complete remission. 310 63

Expression of the activation-associated 4F2 antigen, transferrin receptor and interleukin-2 (IL-2) receptor on suspended cells from 75 biopsied low-grade non-Hodgkin lymphomas (L-NHL) of B-cell origin was correlated to patient survival, clinical prognostic parameters and estimated DNA synthesis. 4F2 antigen expression correlated significantly with poor patient survival, high DNA synthesis and transferrin receptor expression. Transferrin receptor expression was associated with high DNA synthesis and treatment response, but not with patient survival. On the other hand, IL-2 receptor was correlated neither to patient survival nor to other studied markers for cell activation, but seemed to be expressed on certain subsets of lymphomas. We suggest that monoclonal antibody (MAb) against the activation-associated 4F2 antigen could be used to select patients with L-NHL for aggressive chemotherapy.
 ...
PMID:The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas. 310 47

A total of 19 Hodgkin's disease (HD) patients (12 male, 7 female) aged 26-67 years, who had been in complete unmaintained remission for 6 months or more when the study was initiated, were randomly given 50 mg thymostimulin (TS) i.m. daily (G1) or every other day (G2) for 35 days. A third group (G3) was not treated. Then TS, at the same dose was administered twice a week for the following 22 weeks in patients both initially receiving loading or intermittent TS treatment. When compared with age- and sex-matched controls, as a group, the patients' circulating OKT3+, OKT4+, OKT11+ and E-AETR+ cells were depressed (P less than 0.001 for both proportions and absolute numbers), whereas their OKT8+ cell population was not. Following 5 weeks of daily TS administration, the proportions and numbers of all T cell fractions significantly increased in G1 patients (P less than 0.03 for all the comparisons tested), while following intermittent TS treatment (G2) only the proportions of OKT3+ and OKT11+ cells (P less than 0.03), but not of other T cell fractions, significantly increased. In addition, no significant changes in the absolute numbers of T cell fractions were observed in this group of patients. Furthermore, no spontaneous variations in the T cell pool size occurred in untreated patients. TS maintenance therapy did not produce any further improvement in the size of overall T cells and T cell subsets but sustained percentage and absolute numbers of these cells during administration and the absolute number of T cells even after discontinuation of therapy. The TS-induced improvement in the T cell pool was not associated with any change in the size of circulating non-T lymphocytes and monocytes. In vitro phytohemagglutinin-induced interleukin-2 (IL-2) and gamma-interferon (IFN-gamma) synthesis was assessed in 11 patients (3 G1, 4 G2, and 4 G3). Although it was not statistically significant, a rise in IL-2 and IFN-gamma production was observed in TS-treated patients, but not in untreated controls. TS failed to exert any effect on the serum circulating levels of neopterin, type I and II IFN, beta-2 microglobulin (B2-M) and immunoglobulins (Ig). TS can thus improve defective T cell frequences and numbers and may modulate IL-2 and IFN-gamma production.
 ...
PMID:A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin's disease in complete remission. 312 73

The MLR-3 monoclonal antibody reacts with activated but not with resting lymphocytes. We report that MLR-3 identifies an early activation molecule since its binding is detectable on T cells 1.5-2 hr after in vitro activation. Its expression, therefore, does not require DNA synthesis and precedes, by many hours, that of the receptors for interleukin-2 (IL-2R) and transferrin (TF-R). The MLR-3 antigen is also found on activated thymocytes (including the large early thymic CD3- subset) and B cells. The majority of T- and B-lymphoblastoid cell lines, as well as the myeloid and erythroid cell lines HL60, GM1 and K562, are MLR-3+; conversely, non-haemopoietic cell lines are MLR-3 negative. Seventy percent of B-cell chronic lymphocytic leukaemia and 15% of B non-Hodgkin's lymphomas (B-NHL) are MLR-3+. On tissue sections MLR-3 is reactive with epithelia, sweat glands, hair follicles and Henle's loop but not with vessels, connective, endothelium and many other tissues. In vitro studies show that MLR-3 (1-100 micrograms/ml) significantly alters the thymidine uptake of mitogen-treated lymphocytes:augmentation is found when T and B cells are induced with TPA-Ionomycin and reduction when induced with phytohaemoagglutinin (PHA) or Staphylococcus aureus Cowan strain 1 (SAC), respectively. On SDS-PAGE, MLR-3 immunoprecipitates a disulphide-linked heterodimer of MW 29,000-35,000: both subunits are glycosylated, phosphorylated and exhibit a pI of 4.1 and 5.0, respectively. Our data, particularly the in vitro results, suggest that the MRL-3 molecule could have an important role in the early hours of activation for the progression of resting lymphocytes into mitosis.
 ...
PMID:Early lymphocyte activation molecule defined by the monoclonal antibody MLR-3: biochemical and functional studies. 326 71

Peripheral blood mononuclear cells (PBMC) from patients with acute myeloid leukemia (AML) or non-Hodgkin lymphoma (NHL) and healthy controls were stimulated with phytohemagglutinin (PHA) and interleukin-2 (IL-2). PHA (1 microgram/ml) induced higher 3H-thymidine incorporation than 800 U/ml IL-2 in PBMC from both controls and patients with AML in complete remission. A synergistic effect between PHA and IL-2 was found. Malignant B cells from 5/12 NHL expressed IL-2 receptors and showed proliferative response to IL-2, but not to PHA. PHA induced higher cytotoxicity toward AML blasts in lymphocytes from healthy controls than did IL-2. In addition, PHA induced higher cytotoxicity in lymphocytes from healthy controls than in those from patients with AML in remission. In contrast, no difference in cytotoxicity between controls' and patients' lymphocytes was found after stimulation with IL-2. No HLA restriction could be demonstrated. Normal peripheral blood mononuclear cells and leukemic blasts from 2/12 AML were completely resistant to cytotoxic cells even at effector:target ratios four times as high as those otherwise required.
 ...
PMID:Effect of phytohemagglutinin and interleukin-2 on malignant and nonmalignant B and T lymphocytes. 326 4

Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to induce tumor regression in some patients with cancer, but has been associated with severe fluid retention and cardiopulmonary stress. In an effort to preserve the efficacy but reduce the toxicity of this treatment, we used escalating doses of rIL-2 as a constant infusion rather than as a bolus dose. Forty-eight patients with advanced cancer received rIL-2 as a 24-hour infusion in five-day cycles separated by five-day periods of rest and leukapheresis. Eight patients were removed from the study before receiving cells activated in vitro. In the 40 who could be evaluated for their response, there were 13 partial responses (32.5 percent) and 2 minor responses. Partial responses were observed in Hodgkin's disease (one of one), non-Hodgkin's lymphoma (one of one), lung cancer (one of five), ovarian cancer (one of one), parotid cancer (one of two), renal cancer (three of six), and melanoma (five of ten). Responses were associated with a good performance status, a base-line lymphocyte count above 1400 per cubic millimeter, and an rIL-2-induced lymphocyte count of at least 6000. Optimal lymphocytosis required a priming dose of rIL-2 of 3 X 10(6) U per square meter of body-surface area per day, and 15 of 28 patients receiving this priming dose responded to treatment. A weight gain of more than 10 percent of total body weight (five patients) and dyspnea at rest (six patients) were unusual events restricted to patients with poorer pretreatment performance. We conclude that the administration of rIL-2 as a constant infusion may preserve the antineoplastic activity of adoptive immunotherapy while increasing the safety and comfort of patients.
 ...
PMID:Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. 349 33

PHA-induced peripheral blood lymphocyte (PBL) proliferation and T-cell colony formation in soft agar was studied in the presence of interleukin-2 (IL-2) containing medium in untreated Hodgkin disease (HD) patients and normal controls. The proliferative response of HD PBL was potentiated in presence of IL-2-containing medium in 11 of 20 cases studied, and there was marginal increase or inhibition of PHA response in 16 normal lymphocyte samples. Lymphocytes from patients in advanced stages of the disease, and those who were initially hyporesponsive responded better to suboptimal doses of PHA in the presence of exogenous IL-2. There was no improvement in the colony forming capacity of T lymphocytes from HD PBL even in the presence of IL-2-containing medium, whereas normal T-cell colony formation was augmented significantly both in number and in size of colonies.
 ...
PMID:Effect of exogenous interleukins on in vitro responses of T lymphocytes from patients with Hodgkin disease. 349 12

The mitogenic response of T-cell subsets, the production of interleukin-1 (Il-1) and interleukin-2 (Il-2) and in vitro immunoglobulin production was investigated in patients with Hodgkin's disease (HD). The mitogenic response of mononuclear cells (MNC) and the OKT4+ and OKT8+ subsets was greatly reduced in advanced disease stages and could only partially be restored with exogeneous Il-2. In untreated patients with HD--except those with highly advanced disease--the OKT4+ lymphocytes showed normal response to phytohemagglutinin in contrast to the MNC suggesting inhibiting agents or cells within in the MNC. These findings corresponded to reduced Il-2 synthesis of MNC, whereas isolated OKT4+--cells produced normal or elevated amounts of Il-2. MNC or monocytes produced normal or even higher amounts of lipopolysaccharide-induced Il-1 than controls. The results do not confirm a defect in this component of the interleukin system in HD. The immunological impairment was not limited to the T-cell system but involved B-cell activation and differentiation as well. The pokeweed mitogen-induced IgM, IgG and IgG production was highly suppressed in untreated HD, whereas the MNC of previously treated patients produced subnormal amounts of immunoglobulin in vitro. It is not yet clear whether this defect is T-cell-mediated or primarily a B-cell deficiency.
 ...
PMID:Impaired T- and B-cell functions in patients with Hodgkin's disease. Reduced mitogenic responsibility and Il-2 production is not caused by defective CD4+-cells. 349 58

1. The proliferative response of phytohemagglutinin-activated lymphocytes from patients with Hodgkin's and non-Hodgkin's lymphoma was compared to their interleukin-2 (IL-2) production. 2. Impairment in the lymphoproliferative response paralleled a reduction in IL-2 production. 3. Suppressor cells and serum factors which depressed the proliferative response of the patients' lymphocytes inhibited IL-2 production. 4. Enhanced prostaglandin synthesis was one of the factors causing impairment of the proliferative response and the diminished IL-2 production in lymphocytes from patients with lymphoma. 5. A partial restoration of patients' cellular responses in vitro was achieved by adding conditioned media containing IL-1 or IL-2.
 ...
PMID:Impaired proliferative response and low interleukin-2 production in patients with lymphoma. 350 37

The characterization of malignant lymphomas with immunological methods (immunophenotyping) is gaining increasing importance in clinical hematology. Immunophenotyping is not only a basis of modern classifications of non-Hodgkin's lymphomas (e.g. the Kiel classification), it can also be helpful in the differentiation of lymphomas from epithelial or mesenchymal tumors. The immunological identification of subgroups of acute lymphocytic leukemia (c-ALL, T-ALL and B-ALL) bears significant meaning for differential therapy. Other applications of immunophenotyping of malignant lymphomas in the near future will be the demonstration of receptors for certain lymphokines (e.g. for therapy with interleukin-2 or tumor-necrosis-factor), the detection of specific cell surface antigens (for immunotherapy with monoclonal antibodies) and the demonstration of immunological markers for resistance to cytotoxic drugs. A general application of immunophenotyping of malignant lymphomas in clinical hematology will depend on a better standardization of the immunological reagents, a simplification of logistic problems and a significant reduction of the costs.
 ...
PMID:[Clinical relevance of immune phenotyping of malignant lymphomas]. 352 Apr 19


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>